
|
Loading...
Loading...
|
US Pharm. 2010;35(1):14.
Atlanta, GA — Citing low potency, Sanofi Pasteur has recalled about 800,000 pediatric doses of its vaccine against pandemic H1N1 influenza, according to the CDC. The agency, which is not requiring revaccinations, said, “There are no safety concerns with these lots of H1N1 vaccine. All lots successfully passed prerelease testing for purity, potency, and safety.” The recalled doses come from four lots of 0.25-mL prefilled syringes for pediatric use in both 10-packs (lot numbers UT023DA, UT028DA, and UT028CB) and 25-packs (lot number UT030CA). The strength of vaccines can sometimes decline with time, the agency said in a statement on its Web site. Children who were vaccinated with the weakened doses should not be revaccinated because the antigen content “is only slightly below the ‘specified’ range,” the CDC said. That level is still expected to protect against H1N1.
|
Loading...
Loading...
|
|
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.
|